| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
21,390 |
18,237 |
$2.97M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
18,229 |
16,154 |
$1.56M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,038 |
2,665 |
$946K |
| 58662 |
|
962 |
736 |
$441K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
503 |
439 |
$424K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
3,787 |
3,164 |
$376K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,223 |
1,014 |
$293K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
7,204 |
6,212 |
$261K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
408 |
369 |
$243K |
| 71045 |
Radiologic examination, chest; single view |
7,858 |
6,635 |
$230K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
6,506 |
5,434 |
$208K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
7,251 |
1,834 |
$187K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,569 |
2,218 |
$172K |
| 80053 |
Comprehensive metabolic panel |
25,123 |
20,912 |
$171K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,980 |
1,533 |
$158K |
| 59025 |
Fetal non-stress test |
1,573 |
955 |
$144K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
29,636 |
24,173 |
$142K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,914 |
1,716 |
$124K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
271 |
249 |
$83K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,259 |
2,344 |
$73K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,571 |
2,015 |
$60K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
5,404 |
3,991 |
$52K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,066 |
1,634 |
$51K |
| 80061 |
Lipid panel |
4,454 |
4,065 |
$50K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,624 |
1,415 |
$46K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,632 |
1,415 |
$46K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,450 |
1,094 |
$40K |
| 80050 |
General health panel |
948 |
874 |
$39K |
| 80081 |
|
540 |
472 |
$34K |
| C9399 |
Unclassified drugs or biologicals |
8,948 |
3,539 |
$33K |
| 81001 |
|
18,343 |
14,743 |
$33K |
| G0378 |
Hospital observation service, per hour |
516 |
326 |
$32K |
| 71046 |
Radiologic examination, chest; 2 views |
870 |
702 |
$32K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
986 |
769 |
$30K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,404 |
1,020 |
$28K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,551 |
601 |
$26K |
| 84702 |
|
2,865 |
2,338 |
$24K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
4,665 |
3,753 |
$24K |
| 87581 |
|
921 |
745 |
$24K |
| 87486 |
|
912 |
745 |
$24K |
| 84484 |
|
3,538 |
2,975 |
$22K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
71 |
63 |
$22K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,339 |
2,632 |
$22K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
669 |
224 |
$22K |
| 81025 |
|
3,384 |
2,930 |
$22K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
694 |
601 |
$20K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,487 |
2,846 |
$18K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,360 |
1,223 |
$16K |
| 97161 |
|
337 |
328 |
$16K |
| 82553 |
|
3,101 |
2,557 |
$16K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
785 |
697 |
$15K |
| 94760 |
|
6,549 |
4,352 |
$15K |
| 73564 |
|
216 |
124 |
$15K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,281 |
872 |
$14K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,077 |
705 |
$14K |
| 87480 |
|
1,006 |
835 |
$14K |
| 87510 |
|
1,006 |
835 |
$14K |
| 82550 |
|
3,799 |
3,151 |
$13K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
76 |
43 |
$12K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,588 |
1,414 |
$12K |
| 84443 |
Thyroid stimulating hormone (TSH) |
987 |
847 |
$12K |
| 83735 |
|
3,332 |
2,789 |
$11K |
| 85730 |
|
3,920 |
3,244 |
$11K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
844 |
774 |
$11K |
| 72110 |
|
155 |
146 |
$10K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
353 |
292 |
$9K |
| 85610 |
|
4,056 |
3,415 |
$9K |
| 83880 |
|
440 |
389 |
$7K |
| 80306 |
|
675 |
564 |
$7K |
| 87088 |
|
1,263 |
1,016 |
$7K |
| 87070 |
|
879 |
793 |
$7K |
| 83690 |
|
1,370 |
1,193 |
$7K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
2,748 |
1,942 |
$7K |
| 72050 |
|
88 |
85 |
$6K |
| 97597 |
|
433 |
177 |
$6K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
12 |
12 |
$5K |
| 82652 |
|
373 |
307 |
$5K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
145 |
136 |
$5K |
| 87631 |
|
934 |
736 |
$5K |
| 87634 |
|
1,198 |
845 |
$5K |
| 87660 |
|
283 |
234 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
113 |
92 |
$4K |
| A6021 |
Collagen dressing, sterile, size 16 sq. in. or less, each |
920 |
456 |
$4K |
| 82607 |
|
298 |
275 |
$4K |
| 74018 |
|
137 |
125 |
$4K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
17 |
15 |
$4K |
| G0379 |
Direct admission of patient for hospital observation care |
28 |
27 |
$4K |
| 81003 |
|
2,515 |
1,991 |
$3K |
| 86592 |
|
887 |
769 |
$3K |
| 94060 |
|
41 |
40 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
124 |
105 |
$3K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
71 |
58 |
$3K |
| 85660 |
|
578 |
495 |
$2K |
| J2785 |
Injection, regadenoson, 0.1 mg |
12 |
12 |
$2K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
12 |
12 |
$2K |
| 84439 |
|
298 |
265 |
$2K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
419 |
303 |
$2K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
17 |
17 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
174 |
76 |
$2K |
| A6453 |
Self-adherent bandage, elastic, non-knitted/non-woven, width less than three inches, per yard |
1,686 |
1,327 |
$2K |
| 84481 |
|
139 |
129 |
$2K |
| 94726 |
|
41 |
40 |
$2K |
| 80305 |
|
165 |
143 |
$2K |
| 85651 |
|
460 |
389 |
$2K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,732 |
2,168 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
649 |
504 |
$1K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
28 |
26 |
$1K |
| 94729 |
|
41 |
40 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
190 |
176 |
$1K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
225 |
166 |
$1K |
| 86140 |
|
305 |
247 |
$1K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
293 |
180 |
$1K |
| 87807 |
|
86 |
84 |
$1K |
| 72100 |
|
14 |
13 |
$1K |
| 87077 |
|
197 |
176 |
$1K |
| 93041 |
|
40 |
24 |
$978.22 |
| 73565 |
|
33 |
32 |
$831.32 |
| 29581 |
|
132 |
12 |
$815.58 |
| 87150 |
|
27 |
25 |
$807.08 |
| 84466 |
|
72 |
67 |
$803.88 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,678 |
1,992 |
$798.66 |
| 82150 |
|
180 |
160 |
$780.13 |
| 83540 |
|
129 |
122 |
$764.27 |
| 82105 |
|
48 |
46 |
$746.11 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
48 |
38 |
$577.39 |
| 73502 |
|
16 |
12 |
$559.68 |
| 73110 |
|
16 |
12 |
$533.00 |
| 86038 |
|
52 |
43 |
$507.78 |
| 87186 |
|
137 |
116 |
$506.15 |
| 87340 |
|
72 |
64 |
$489.29 |
| 81015 |
|
1,950 |
1,387 |
$479.66 |
| 73630 |
|
14 |
14 |
$434.88 |
| 82043 |
|
83 |
78 |
$433.12 |
| 82677 |
|
19 |
19 |
$422.81 |
| 82728 |
|
51 |
43 |
$412.31 |
| 80299 |
|
39 |
30 |
$410.08 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
808 |
277 |
$397.13 |
| 83550 |
|
137 |
122 |
$391.96 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
15 |
13 |
$390.66 |
| 84100 |
|
87 |
84 |
$368.40 |
| 84403 |
|
15 |
14 |
$361.34 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
101 |
55 |
$355.13 |
| 85379 |
|
42 |
41 |
$346.12 |
| 86762 |
|
36 |
31 |
$280.76 |
| 86336 |
|
19 |
19 |
$272.56 |
| 86431 |
|
46 |
43 |
$232.47 |
| J2704 |
Injection, propofol, 10 mg |
2,013 |
1,645 |
$224.56 |
| 84145 |
|
15 |
14 |
$193.26 |
| 87015 |
|
42 |
27 |
$187.04 |
| 86850 |
|
54 |
47 |
$183.01 |
| 87081 |
|
27 |
27 |
$165.19 |
| 87040 |
|
20 |
12 |
$137.64 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
269 |
246 |
$112.43 |
| 83605 |
|
17 |
15 |
$104.13 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
120 |
90 |
$83.58 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
472 |
329 |
$80.00 |
| 86900 |
|
41 |
34 |
$64.32 |
| 86901 |
|
41 |
34 |
$64.32 |
| 84550 |
|
15 |
13 |
$55.37 |
| 82947 |
|
24 |
15 |
$55.02 |
| 82950 |
|
13 |
12 |
$49.37 |
| 36000 |
|
120 |
72 |
$46.05 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
249 |
129 |
$36.00 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
150 |
119 |
$9.44 |
| 84156 |
|
22 |
16 |
$3.67 |
| A6402 |
Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing |
1,325 |
998 |
$2.39 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
12 |
12 |
$0.00 |
| 58120 |
|
279 |
144 |
$0.00 |
| 82570 |
|
21 |
15 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
49 |
44 |
$0.00 |
| J0689 |
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg |
19 |
14 |
$0.00 |
| 70320 |
|
379 |
339 |
$0.00 |
| J7121 |
5% dextrose in lactated ringers infusion, up to 1000 cc |
147 |
55 |
$0.00 |
| A6455 |
Self-adherent bandage, elastic, non-knitted/non-woven, width greater than or equal to five inches, per yard |
13 |
12 |
$0.00 |